1
|
Cumming IA, Degorce SL, Aagaard A, Braybrooke EL, Davies NL, Diène CR, Eatherton AJ, Felstead HR, Groombridge SD, Lenz EM, Li Y, Nai Y, Pearson S, Robb GR, Scott JS, Steward OR, Wu C, Xue Y, Zhang L, Zhang Y. Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors. Bioorg Med Chem 2022; 63:116729. [PMID: 35439688 DOI: 10.1016/j.bmc.2022.116729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 03/23/2022] [Accepted: 03/28/2022] [Indexed: 12/01/2022]
Abstract
In this article, we report the discovery of a series of pyrimidopyridones as inhibitors of IRAK4 kinase. From a previously disclosed 5-azaquinazoline series, we found that switching the pyridine ring for an N-substituted pyridone gave a novel hinge binding scaffold which retained potency against IRAK4. Importantly, introduction of the carbonyl established an internal hydrogen bond with the 4-NH, establishing a conformational lock and allowing truncation of the large basic substituent to a 1-methylcyclopyl group. Subsequent optimisation, facilitated by X-ray crystal structures, allowed identification of preferred substituents at both the pyridone core and pyrazole. Subsequent combinations of optimal groups allowed control of lipophilicity and identification of potent and selective inhibitors of IRAK4 with better in vitro permeability and lower clearance.
Collapse
Affiliation(s)
- Iain A Cumming
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom.
| | - Sébastien L Degorce
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - Anna Aagaard
- Discovery Sciences, R&D, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden
| | - Erin L Braybrooke
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - Nichola L Davies
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - Coura R Diène
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - Andrew J Eatherton
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - Hannah R Felstead
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - Sam D Groombridge
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - Eva M Lenz
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - Yunxia Li
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176 PR China
| | - Youfeng Nai
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176 PR China
| | - Stuart Pearson
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - Graeme R Robb
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - James S Scott
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - Oliver R Steward
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - Chengyan Wu
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176 PR China
| | - Yafeng Xue
- Discovery Sciences, R&D, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden
| | - Lanping Zhang
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176 PR China
| | - Yanxiu Zhang
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176 PR China
| |
Collapse
|
2
|
Scott JS, Bailey A, Buttar D, Carbajo RJ, Curwen J, Davey PRJ, Davies RDM, Degorce SL, Donald C, Gangl E, Greenwood R, Groombridge SD, Johnson T, Lamont S, Lawson M, Lister A, Morrow CJ, Moss TA, Pink JH, Polanski R. Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists. J Med Chem 2019; 62:1593-1608. [PMID: 30640465 DOI: 10.1021/acs.jmedchem.8b01837] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Herein, we report the identification and synthesis of a series of tricyclic indazoles as a novel class of selective estrogen receptor degrader antagonists. Replacement of a phenol, present in our previously reported tetrahydroisoquinoline scaffold, with an indazole group led to the removal of a reactive metabolite signal in an in vitro glutathione trapping assay. Further optimization, guided by X-ray crystal structures and NMR conformational work, varied the alkyl side chain and pendant aryl group and resulted in compounds with low turnover in human hepatocytes and enhanced chemical stability. Compound 9 was profiled as a representative of the series in terms of pharmacology and demonstrated the desired estrogen receptor α degrader-antagonist profile and demonstrated activity in a xenograft model of breast cancer.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Eric Gangl
- Oncology IMED Biotech Unit , AstraZeneca, R&D Boston , 35 Gatehouse Drive , Waltham , Massachusetts 02451 , United States
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Degorce SL, Anjum R, Dillman KS, Drew L, Groombridge SD, Halsall CT, Lenz EM, Lindsay NA, Mayo MF, Pink JH, Robb GR, Scott JS, Stokes S, Xue Y. Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4. Bioorg Med Chem 2018; 26:913-924. [DOI: 10.1016/j.bmc.2018.01.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Revised: 01/10/2018] [Accepted: 01/12/2018] [Indexed: 10/18/2022]
|
4
|
Scott JS, Degorce SL, Anjum R, Culshaw J, Davies RDM, Davies NL, Dillman KS, Dowling JE, Drew L, Ferguson AD, Groombridge SD, Halsall CT, Hudson JA, Lamont S, Lindsay NA, Marden SK, Mayo MF, Pease JE, Perkins DR, Pink JH, Robb GR, Rosen A, Shen M, McWhirter C, Wu D. Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma. J Med Chem 2017; 60:10071-10091. [DOI: 10.1021/acs.jmedchem.7b01290] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- James S. Scott
- Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom
| | | | - Rana Anjum
- Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States
| | - Janet Culshaw
- Oncology,
IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom
| | - Robert D. M. Davies
- Oncology,
IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom
| | - Nichola L. Davies
- Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom
| | - Keith S. Dillman
- Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States
| | - James E. Dowling
- Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States
| | - Lisa Drew
- Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States
| | - Andrew D. Ferguson
- Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States
| | - Sam D. Groombridge
- Oncology,
IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom
| | | | - Julian A. Hudson
- Oncology,
IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom
| | - Scott Lamont
- Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom
| | - Nicola A. Lindsay
- Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom
| | - Stacey K. Marden
- Pharmaceutical
Sciences, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States
| | - Michele F. Mayo
- Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States
| | - J. Elizabeth Pease
- Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom
| | - David R. Perkins
- Oncology,
IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom
| | - Jennifer H. Pink
- Oncology,
IMED Biotech Unit, AstraZeneca, Macclesfield SK10 4TG, United Kingdom
| | - Graeme R. Robb
- Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom
| | - Alan Rosen
- Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States
| | - Minhui Shen
- Oncology,
IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States
| | - Claire McWhirter
- Oncology,
IMED Biotech Unit, AstraZeneca, Cambridge CB4 0FZ, United Kingdom
| | - Dedong Wu
- Pharmaceutical
Sciences, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States
| |
Collapse
|
5
|
Waring MJ, Baker DJ, Bennett SNL, Dossetter AG, Fenwick M, Garcia R, Georgsson J, Groombridge SD, Loxham S, MacFaul PA, Maskill KG, Morgan D, Morrell J, Pointon H, Robb GR, Smith DM, Stokes S, Wilkinson G. Discovery of a series of 2-(pyridinyl)pyrimidines as potent antagonists of GPR40. Med Chem Commun 2015. [DOI: 10.1039/c5md00037h] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
A series of 2-(pyridinyl)pyrimidines were identified as potent GPR40 antagonists.
Collapse
|
6
|
Goldberg FW, Dossetter AG, Scott JS, Robb GR, Boyd S, Groombridge SD, Kemmitt PD, Sjögren T, Gutierrez PM, deSchoolmeester J, Swales JG, Turnbull AV, Wild MJ. Optimization of Brain Penetrant 11β-Hydroxysteroid Dehydrogenase Type I Inhibitors and in Vivo Testing in Diet-Induced Obese Mice. J Med Chem 2014; 57:970-86. [DOI: 10.1021/jm4016729] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
| | | | - James S. Scott
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, United Kingdom
| | - Graeme R. Robb
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, United Kingdom
| | - Scott Boyd
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, United Kingdom
| | - Sam D. Groombridge
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, United Kingdom
| | - Paul D. Kemmitt
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, United Kingdom
| | - Tove Sjögren
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, United Kingdom
| | | | | | - John G. Swales
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, United Kingdom
| | - Andrew V. Turnbull
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, United Kingdom
| | - Martin J. Wild
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, United Kingdom
| |
Collapse
|
7
|
Scott JS, Brocklehurst KJ, Brown HS, Clarke DS, Coe H, Groombridge SD, Laber D, MacFaul PA, McKerrecher D, Schofield P. Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human. Bioorg Med Chem Lett 2013; 23:3175-9. [PMID: 23628336 DOI: 10.1016/j.bmcl.2013.04.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Revised: 03/28/2013] [Accepted: 04/02/2013] [Indexed: 02/07/2023]
Abstract
A series of conformationally restricted GPR119 agonists were prepared based around a 3,8-diazabicyclo[3.2.1]octane scaffold. Examples were found to have markedly different pharmacology in mouse and human despite similar levels of binding to the receptor. This highlights the large effects on GPCR phamacology that can result from small structural changes in the ligand, together with inter-species differences between receptors.
Collapse
Affiliation(s)
- James S Scott
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Scott JS, Birch AM, Brocklehurst KJ, Brown HS, Goldberg K, Groombridge SD, Hudson JA, Leach AG, MacFaul PA, McKerrecher D, Poultney R, Schofield P, Svensson PH. Optimisation of aqueous solubility in a series of G protein coupled receptor 119 (GPR119) agonists. Med Chem Commun 2013. [DOI: 10.1039/c2md20130e] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Solubility improvements in a series of GPR119 agonists are achieved through reduction of lipophilicity together with hydrogen bond acceptor modulation.
Collapse
|
9
|
Goldberg FW, Birch AM, Leach AG, Groombridge SD, Snelson WL, Gutierrez PM, Hammond CD, Birtles S, Buckett LK. Discovery and optimization of efficacious neutral 4-amino-6-biphenyl-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one diacylglycerol acyl transferase-1 (DGAT1) inhibitors. Med Chem Commun 2013. [DOI: 10.1039/c2md20231j] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Neutral DGAT1 inhibitors have been designed with comparable pre-clinical efficacy and PK/PD to those previously described for acidic inhibitors.
Collapse
|
10
|
Goldberg FW, Leach AG, Scott JS, Snelson WL, Groombridge SD, Donald CS, Bennett SNL, Bodin C, Gutierrez PM, Gyte AC. Free-Wilson and Structural Approaches to Co-optimizing Human and Rodent Isoform Potency for 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors. J Med Chem 2012; 55:10652-61. [DOI: 10.1021/jm3013163] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | - Andrew G. Leach
- AstraZeneca, Mereside, Alderley
Park, Macclesfield, SK10 4TG, United Kingdom
| | - James S. Scott
- AstraZeneca, Mereside, Alderley
Park, Macclesfield, SK10 4TG, United Kingdom
| | - Wendy L. Snelson
- AstraZeneca, Mereside, Alderley
Park, Macclesfield, SK10 4TG, United Kingdom
| | - Sam D. Groombridge
- AstraZeneca, Mereside, Alderley
Park, Macclesfield, SK10 4TG, United Kingdom
| | - Craig S. Donald
- AstraZeneca, Mereside, Alderley
Park, Macclesfield, SK10 4TG, United Kingdom
| | | | - Cristian Bodin
- AstraZeneca, Mereside, Alderley
Park, Macclesfield, SK10 4TG, United Kingdom
| | | | - Amy C. Gyte
- AstraZeneca, Mereside, Alderley
Park, Macclesfield, SK10 4TG, United Kingdom
| |
Collapse
|
11
|
Scott JS, Gill AL, Godfrey L, Groombridge SD, Rees A, Revill J, Schofield P, Sörme P, Stocker A, Swales JG, Whittamore PRO. Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors. Bioorg Med Chem Lett 2012; 22:6756-61. [PMID: 23013933 DOI: 10.1016/j.bmcl.2012.08.070] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2012] [Revised: 08/14/2012] [Accepted: 08/16/2012] [Indexed: 11/25/2022]
Abstract
11β-HSD1 is increasingly seen as an attractive target for the treatment of type II diabetes and other elements of the metabolic syndrome. In this program of work we describe how a series of neutral 2-thioalkyl-pyridine 11β-HSD1 inhibitors were optimized in terms of their pharmacokinetic properties to give compounds with excellent bioavailability in both rat and dog through a core change to pyrimidine. A potential reactive metabolite issue with 4-thioalkyl-pyrimidines was circumvented by a switch from sulfur to carbon substitution.
Collapse
Affiliation(s)
- James S Scott
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Scott JS, Birch AM, Brocklehurst KJ, Broo A, Brown HS, Butlin RJ, Clarke DS, Davidsson Ö, Ertan A, Goldberg K, Groombridge SD, Hudson JA, Laber D, Leach AG, MacFaul PA, McKerrecher D, Pickup A, Schofield P, Svensson PH, Sörme P, Teague J. Use of Small-Molecule Crystal Structures To Address Solubility in a Novel Series of G Protein Coupled Receptor 119 Agonists: Optimization of a Lead and in Vivo Evaluation. J Med Chem 2012; 55:5361-79. [DOI: 10.1021/jm300310c] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- James S. Scott
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Alan M. Birch
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Katy J. Brocklehurst
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Anders Broo
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Pepparedsleden 1, 431 83 Mölndal, Sweden
| | - Hayley S. Brown
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Roger J. Butlin
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - David S. Clarke
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Öjvind Davidsson
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Pepparedsleden 1, 431 83 Mölndal, Sweden
| | - Anne Ertan
- Pharmaceutical Development, AstraZeneca R&D, S-151 85 Södertälje, Sweden
| | - Kristin Goldberg
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Sam D. Groombridge
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Julian A. Hudson
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - David Laber
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Andrew G. Leach
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Philip A. MacFaul
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Darren McKerrecher
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Adrian Pickup
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Paul Schofield
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Per H. Svensson
- Pharmaceutical Development, AstraZeneca R&D, S-151 85 Södertälje, Sweden
| | - Pernilla Sörme
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Joanne Teague
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| |
Collapse
|
13
|
Waring MJ, Clarke DS, Fenwick MD, Godfrey L, Groombridge SD, Johnstone C, McKerrecher D, Pike KG, Rayner JW, Robb GR, Wilson I. Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656. Med Chem Commun 2012. [DOI: 10.1039/c2md20077e] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|